Jean-Marc Treluyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jean-Marc Treluyer has a total of 388 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Chouchana
Pharmacovigilance Regional Centre, Pharmacology Department, Cochin Hospital, APHP UMR1343 INSERM Université Paris Cité Paris France
21 shared publications Sihem Benaboud
Department of Clinical Pharmacology Cochin Hospital Paris Ile‐de‐France France
9 shared publications- Mehdi Oualha
Pediatric Intensive Care Unit, Necker Hospital, APHP, Centre - Paris University, Paris, France
8 shared publications - Frantz Foissac
U1343, Pharmacologie et Évaluations Thérapeutiques Chez L'enfant et la Femme Enceinte Inserm, Université Paris Cité Paris France
5 shared publications Sylvain Renolleau
Department of Pediatric Intensive Care Necker‐Enfants Malades Hospital, AP‐HP.Centre, Université Paris Cité Paris Ile‐de‐France France
5 shared publicationsDelphine Callot
Regional Pharmacovigilance Center Cochin Hospital Paris Ile‐de‐France France
4 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Cefepime exposure in prolonged or intermittent infusion in critically ill children
Aims: Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient. The aim of this study was to compare cefepime exposure between prolonged and intermittent infusions in critically ill children. Methods: This prospective observational study was conducted in two paediatric intensive care units. Children with a cefepime plasma concentration measurement were included. Steady‐state free residual and plateau concentrations were estimated using Bayesian forecasting. The PK target was defined as 100% f T ≥4xMIC . Exposure was compared using the minimum inhibitory concentrations (MICs) of the pathogens identified in the patients. The probability of target attainment (PTA) was also compared using various MICs. Results: Seventy‐eight antibiotic courses in 75 patients were included, divided into 19 prolonged infusions and 59 intermittent infusions. Prolonged and intermittent infusions were comparable for optimal exposure ( n = 10/19, 53% vs. n = 35/59, 59%, p = .79). Overexposure tended to be more frequent with prolonged infusion ( n = 8/19, 42% vs. n = 16/59, 27%, p = .26), whereas underexposure tended to be less common with prolonged infusion ( n = 1/19, 5% vs. n = 8/59, 14%, p = .44). Considering the wide range of MICs, the PTA was comparable for MIC < 1 mg/L but was significantly higher for prolonged infusion for MIC ≥ 1 mg/L ( p < .05). Conclusion: Prolonged infusion of cefepime provides a higher PTA when MIC is ≥1 mg/L compared with intermittent infusion. This result suggests the superiority of prolonged infusion for high MIC bacteria.
- 10 September 2026
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessCefepime exposure in prolonged or intermittent infusion in critically ill children
Aims: Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient. The aim of this study was to compare cefepime exposure between prolonged and intermittent infusions in critically ill children. Methods: This prospective observational study was conducted in two paediatric intensive care units. Children with a cefepime plasma concentration measurement were included. Steady‐state free residual and plateau concentrations were estimated using Bayesian forecasting. The PK target was defined as 100% f T ≥4xMIC . Exposure was compared using the minimum inhibitory concentrations (MICs) of the pathogens identified in the patients. The probability of target attainment (PTA) was also compared using various MICs. Results: Seventy‐eight antibiotic courses in 75 patients were included, divided into 19 prolonged infusions and 59 intermittent infusions. Prolonged and intermittent infusions were comparable for optimal exposure ( n = 10/19, 53% vs. n = 35/59, 59%, p = .79). Overexposure tended to be more frequent with prolonged infusion ( n = 8/19, 42% vs. n = 16/59, 27%, p = .26), whereas underexposure tended to be less common with prolonged infusion ( n = 1/19, 5% vs. n = 8/59, 14%, p = .44). Considering the wide range of MICs, the PTA was comparable for MIC < 1 mg/L but was significantly higher for prolonged infusion for MIC ≥ 1 mg/L ( p < .05). Conclusion: Prolonged infusion of cefepime provides a higher PTA when MIC is ≥1 mg/L compared with intermittent infusion. This result suggests the superiority of prolonged infusion for high MIC bacteria.
- 6 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (9) , 1138-1147
Piperacillin Population Pharmacokinetics in Children Supported With Extracorporeal Membrane Oxygenation
OBJECTIVE: To characterize piperacillin population pharmacokinetics (PK) in critically ill children with and without extracorporeal membrane oxygenation (ECMO) support and to optimize piperacillin dosing regimens to attain the PK target of 100% free time above minimum inhibitory concentration (fT > minimum inhibitory concentration). DESIGN: Post hoc secondary analysis of a two-center, population PK modeling and simulation study (registered at clinicaltrials.gov, NCT02539407). SETTINGS: PICUs at tertiary care centers, September 2015–November 2021. PATIENTS: Thirty-three children supported with ECMO and 50 non-ECMO control patients treated with piperacillin (± tazobactam). INTERVENTIONS: Administration of piperacillin at 300 mg/kg/d by continuous infusion or 75 mg/kg every 6 hours by intermittent infusion. MEASUREMENTS AND MAIN RESULTS: A one-compartment linear-elimination model described best the piperacillin data. Clearance was driven by body weight and estimated glomerular filtration rate (eGFR). In a typical 11-kg patient, ECMO circuit volume-to-weight ratio increased the volume of distribution by 34%. Monte Carlo simulations across eGFR strata (30–60, 60–90, 90–150, 150–200, 200–300 mL/min/1.73 m 2 ) showed that a continuous infusion of 300 mg/kg/d allowed greater than or equal to 90% of target attainment in all groups. Patients with an eGFR greater than 200 mL/min/1.73 m 2 required 400 mg/kg/d to have 90% of target attainment. CONCLUSIONS: Continuous infusion of 300 mg/kg/d piperacillin reliably achieves PK target across all renal‐function ranges in children undergoing support with ECMO. Dose escalation to 400 mg/kg/d is required for augmented renal clearance (eGFR > 200 mL/min/1.73 m 2 ).
- 6 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (9) , 1138-1147
Piperacillin Population Pharmacokinetics in Children Supported With Extracorporeal Membrane Oxygenation
OBJECTIVE: To characterize piperacillin population pharmacokinetics (PK) in critically ill children with and without extracorporeal membrane oxygenation (ECMO) support and to optimize piperacillin dosing regimens to attain the PK target of 100% free time above minimum inhibitory concentration (fT > minimum inhibitory concentration). DESIGN: Post hoc secondary analysis of a two-center, population PK modeling and simulation study (registered at clinicaltrials.gov, NCT02539407). SETTINGS: PICUs at tertiary care centers, September 2015–November 2021. PATIENTS: Thirty-three children supported with ECMO and 50 non-ECMO control patients treated with piperacillin (± tazobactam). INTERVENTIONS: Administration of piperacillin at 300 mg/kg/d by continuous infusion or 75 mg/kg every 6 hours by intermittent infusion. MEASUREMENTS AND MAIN RESULTS: A one-compartment linear-elimination model described best the piperacillin data. Clearance was driven by body weight and estimated glomerular filtration rate (eGFR). In a typical 11-kg patient, ECMO circuit volume-to-weight ratio increased the volume of distribution by 34%. Monte Carlo simulations across eGFR strata (30–60, 60–90, 90–150, 150–200, 200–300 mL/min/1.73 m 2 ) showed that a continuous infusion of 300 mg/kg/d allowed greater than or equal to 90% of target attainment in all groups. Patients with an eGFR greater than 200 mL/min/1.73 m 2 required 400 mg/kg/d to have 90% of target attainment. CONCLUSIONS: Continuous infusion of 300 mg/kg/d piperacillin reliably achieves PK target across all renal‐function ranges in children undergoing support with ECMO. Dose escalation to 400 mg/kg/d is required for augmented renal clearance (eGFR > 200 mL/min/1.73 m 2 ).
- Open Access
- 25 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , 3202-3213
Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
Aim: The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK. Method: As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix® software. Results: A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44 L/h) and of ivacaftor (9.64 to 11.36 L/h), indicating a decrease in systemic exposure. Conclusion: These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.
- 25 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , 3202-3213
Open AccessPregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
Aim: The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK. Method: As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix® software. Results: A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44 L/h) and of ivacaftor (9.64 to 11.36 L/h), indicating a decrease in systemic exposure. Conclusion: These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.
- 3 November 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 46 (1) , 57-72
Trends of Opioids and Nefopam Use Among French Children: A Population-Based Study From 2009 to 2023
Background and objectives Effective pain management in children is a public health priority, while opioid-related risks remain a major concern. The aim of the present study was to describe trends of opioids and nefopam use in children in France. Methods We conducted a nationwide drug utilization study using the French National Health Data System (SNDS), covering > 98% of the French population. All children with at least one prescription for a weak opioid, strong opioid, or nefopam between 2009 and 2023 were included. Annual prevalence of use was estimated per 1000 children, stratified by age group (< 2, 2–6, 7–11, 12–17 years). Joinpoint regression was used to analyze temporal trends. Contraindicated use was defined according to age restrictions in marketing authorizations. Results Overall, 4,443,648 children were included in the study. Overall prevalence of analgesic use increased from 22.7‰ in 2009 to 27.4‰ in 2023, mainly driven by weak opioids (26.3‰ in 2023). In 2023, tramadol was the most prescribed weak opioid (13.5‰), followed by codeine (10.1‰). Nefopam use, contraindicated for use under 15 years of age, rose sharply to 1.9‰. Strong opioids, notably morphine and oxycodone, steadily increased but remained low (0.4‰ and 0.08‰, respectively). Most children receiving prescriptions were aged 12–17 years, although weak opioid use declined in this group over the study period. In contrast, children aged 2–6 years showed a fivefold increase in overall analgesic use, driven almost entirely by tramadol, which increased eightfold, while codeine use declined. Contraindicated use remained frequent for tramadol, codeine, opium powder, and nefopam, increasing as children approached the minimal approved age. Conclusion Tramadol was the most commonly prescribed opioid used in pediatric outpatients in France in 2023, followed by codeine. Tramadol off-label use steadily increased, whereas codeine off-label use decreased. The sharp rise in tramadol, especially in children aged 2–6 years, and nefopam prescribing, together with increasing morphine and oxycodone use, in association with frequent contraindicated use, underscores the need for enhanced surveillance and pediatric-specific safety data.
- 3 November 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 46 (1) , 57-72
Trends of Opioids and Nefopam Use Among French Children: A Population-Based Study From 2009 to 2023
Background and objectives Effective pain management in children is a public health priority, while opioid-related risks remain a major concern. The aim of the present study was to describe trends of opioids and nefopam use in children in France. Methods We conducted a nationwide drug utilization study using the French National Health Data System (SNDS), covering > 98% of the French population. All children with at least one prescription for a weak opioid, strong opioid, or nefopam between 2009 and 2023 were included. Annual prevalence of use was estimated per 1000 children, stratified by age group (< 2, 2–6, 7–11, 12–17 years). Joinpoint regression was used to analyze temporal trends. Contraindicated use was defined according to age restrictions in marketing authorizations. Results Overall, 4,443,648 children were included in the study. Overall prevalence of analgesic use increased from 22.7‰ in 2009 to 27.4‰ in 2023, mainly driven by weak opioids (26.3‰ in 2023). In 2023, tramadol was the most prescribed weak opioid (13.5‰), followed by codeine (10.1‰). Nefopam use, contraindicated for use under 15 years of age, rose sharply to 1.9‰. Strong opioids, notably morphine and oxycodone, steadily increased but remained low (0.4‰ and 0.08‰, respectively). Most children receiving prescriptions were aged 12–17 years, although weak opioid use declined in this group over the study period. In contrast, children aged 2–6 years showed a fivefold increase in overall analgesic use, driven almost entirely by tramadol, which increased eightfold, while codeine use declined. Contraindicated use remained frequent for tramadol, codeine, opium powder, and nefopam, increasing as children approached the minimal approved age. Conclusion Tramadol was the most commonly prescribed opioid used in pediatric outpatients in France in 2023, followed by codeine. Tramadol off-label use steadily increased, whereas codeine off-label use decreased. The sharp rise in tramadol, especially in children aged 2–6 years, and nefopam prescribing, together with increasing morphine and oxycodone use, in association with frequent contraindicated use, underscores the need for enhanced surveillance and pediatric-specific safety data.
- Open Access
- 29 July 2025
- Published by Wiley
Cefepime exposure in prolonged or intermittent infusion in critically ill children
Introduction : Cefepime is commonly used in critically ill children for whom there is a high between subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, beta-lactams prolonged infusion seems to be the most efficient. The aim of this study was to compare cefepime exposure between prolonged and intermittent infusions in critically ill children. Methods : This prospective observational study was conducted in two pediatric intensive care units. Children with a cefepime plasma concentration measurement were included. Steady-state free residual and plateau concentrations were estimated using Bayesian forecasting. The PK target was defined as 100% f T ≥4xMIC . Exposure was compared using the minimum inhibitory concentrations (MIC) of the pathogens identified in the patients. The probability of target attainment (PTA) was also compared using various MICs. Results : Seventy-eight antibiotic courses in 75 patients were included, divided into 19 prolonged infusions and 59 intermittent infusions. Prolonged and intermittent infusions were comparable for optimal exposure (n=10/19, 53% vs n=35/59, 59%, p=0.79). Overexposure tended to be more frequent with prolonged infusion (n=8/19, 42% vs n=16/59, 27%, p=0.26), while underexposure tended to be less common with prolonged infusion (n=1/19, 5% vs n=8/59, 14%, p=0.44). Considering the wide range of MICs, the PTA was comparable for MIC < 1 mg/L, but was significantly higher for prolonged infusion for MIC ≥ 1 mg/L (pConclusion : Prolonged infusion of cefepime provides a higher PTA when MIC is ≥ 1 mg/L compared with intermittent infusion. This result suggests the superiority of prolonged infusion for high MIC bacteria.
- 29 July 2025
- Published by Wiley
Open AccessCefepime exposure in prolonged or intermittent infusion in critically ill children
Introduction : Cefepime is commonly used in critically ill children for whom there is a high between subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, beta-lactams prolonged infusion seems to be the most efficient. The aim of this study was to compare cefepime exposure between prolonged and intermittent infusions in critically ill children. Methods : This prospective observational study was conducted in two pediatric intensive care units. Children with a cefepime plasma concentration measurement were included. Steady-state free residual and plateau concentrations were estimated using Bayesian forecasting. The PK target was defined as 100% f T ≥4xMIC . Exposure was compared using the minimum inhibitory concentrations (MIC) of the pathogens identified in the patients. The probability of target attainment (PTA) was also compared using various MICs. Results : Seventy-eight antibiotic courses in 75 patients were included, divided into 19 prolonged infusions and 59 intermittent infusions. Prolonged and intermittent infusions were comparable for optimal exposure (n=10/19, 53% vs n=35/59, 59%, p=0.79). Overexposure tended to be more frequent with prolonged infusion (n=8/19, 42% vs n=16/59, 27%, p=0.26), while underexposure tended to be less common with prolonged infusion (n=1/19, 5% vs n=8/59, 14%, p=0.44). Considering the wide range of MICs, the PTA was comparable for MIC < 1 mg/L, but was significantly higher for prolonged infusion for MIC ≥ 1 mg/L (pConclusion : Prolonged infusion of cefepime provides a higher PTA when MIC is ≥ 1 mg/L compared with intermittent infusion. This result suggests the superiority of prolonged infusion for high MIC bacteria.
- Open Access
- 21 July 2025
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 146 (6) , 851-859
Pregnancy-Related Complications in Osteogenesis Imperfecta
OBJECTIVE: To evaluate obstetric and perinatal outcomes of pregnancies among patients with osteogenesis imperfecta using the French National Health Insurance Database. METHODS: We conducted a retrospective cohort study. Pregnancies were identified with an algorithm specifically developed for the French National Health Insurance Database to identify delivery stays using a combination of International Classification of Diseases, Tenth Revision (ICD-10) discharge codes and medical procedures. Exposure was osteogenesis imperfecta status based on the occurrence of ICD-10 code Q780 5 years before conception or during pregnancy. Outcomes included pregnancy, delivery, postpartum, and fetal complications based on hospital discharge data and reimbursements of medical procedures, medical devices, and drugs. Multivariable logistic regression analysis was performed, adjusted for multiple pregnancies per participant with generalized estimating equations. RESULTS: The cohort included 8,850,969 pregnancies (5,823,322 patients) between January 2012 and December 2023. In total, 408 pregnant individuals (4.6/100,000) were identified with osteogenesis imperfecta. Compared with pregnant individuals without osteogenesis imperfecta, pregnant individuals with osteogenesis imperfecta had increased risks of antepartum hemorrhage (adjusted risk ratio [RR] 1.78, 95% CI, 1.01–3.14), chorioamnionitis (adjusted RR 2.79, 95% CI, 1.17–6.64), malpresentation (adjusted RR 1.65, 95% CI, 1.19–2.30), and preterm delivery (adjusted RR 2.11, 95% CI, 1.62–2.74). Cesarean delivery rates were notably higher in pregnant individuals with osteogenesis imperfecta (adjusted RR 2.59, 95% CI, 2.34–2.88), including among nulliparous individuals (adjusted RR 2.50, 95% CI, 2.22–2.81). Osteogenesis imperfecta was associated with major congenital anomalies (adjusted RR 5.04, 95% CI, 3.97–6.39 overall; adjusted RR 1.67, 95% CI, 1.09–2.56 when osteogenesis imperfecta was excluded from the congenital anomaly definition), especially cardiac anomalies. Postpartum analysis indicated no significant increase in fracture rates compared with prepregnancy periods. CONCLUSION: In this nationwide cohort study, osteogenesis imperfecta was associated with both maternal and fetal complications. These findings underscore the need for specialized, multidisciplinary management of pregnancies in patients with osteogenesis imperfecta.
- 21 July 2025
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 146 (6) , 851-859
Open AccessPregnancy-Related Complications in Osteogenesis Imperfecta
OBJECTIVE: To evaluate obstetric and perinatal outcomes of pregnancies among patients with osteogenesis imperfecta using the French National Health Insurance Database. METHODS: We conducted a retrospective cohort study. Pregnancies were identified with an algorithm specifically developed for the French National Health Insurance Database to identify delivery stays using a combination of International Classification of Diseases, Tenth Revision (ICD-10) discharge codes and medical procedures. Exposure was osteogenesis imperfecta status based on the occurrence of ICD-10 code Q780 5 years before conception or during pregnancy. Outcomes included pregnancy, delivery, postpartum, and fetal complications based on hospital discharge data and reimbursements of medical procedures, medical devices, and drugs. Multivariable logistic regression analysis was performed, adjusted for multiple pregnancies per participant with generalized estimating equations. RESULTS: The cohort included 8,850,969 pregnancies (5,823,322 patients) between January 2012 and December 2023. In total, 408 pregnant individuals (4.6/100,000) were identified with osteogenesis imperfecta. Compared with pregnant individuals without osteogenesis imperfecta, pregnant individuals with osteogenesis imperfecta had increased risks of antepartum hemorrhage (adjusted risk ratio [RR] 1.78, 95% CI, 1.01–3.14), chorioamnionitis (adjusted RR 2.79, 95% CI, 1.17–6.64), malpresentation (adjusted RR 1.65, 95% CI, 1.19–2.30), and preterm delivery (adjusted RR 2.11, 95% CI, 1.62–2.74). Cesarean delivery rates were notably higher in pregnant individuals with osteogenesis imperfecta (adjusted RR 2.59, 95% CI, 2.34–2.88), including among nulliparous individuals (adjusted RR 2.50, 95% CI, 2.22–2.81). Osteogenesis imperfecta was associated with major congenital anomalies (adjusted RR 5.04, 95% CI, 3.97–6.39 overall; adjusted RR 1.67, 95% CI, 1.09–2.56 when osteogenesis imperfecta was excluded from the congenital anomaly definition), especially cardiac anomalies. Postpartum analysis indicated no significant increase in fracture rates compared with prepregnancy periods. CONCLUSION: In this nationwide cohort study, osteogenesis imperfecta was associated with both maternal and fetal complications. These findings underscore the need for specialized, multidisciplinary management of pregnancies in patients with osteogenesis imperfecta.
- Open Access
- 23 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (10) , 2854-2864
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity
Aims: Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE) to forecast free prednisolone concentrations and its association with disease activity.Methods: A total of 66 active SLE patients (adults and children) were included, and followed up prospectively (242 observations available). Plasma prednisolone concentrations were assessed using liquid chromatography‐mass spectrometry, and the data were analysed using Monolix software. The pharmacokinetic model was a one‐compartment open model with absorption lag time representing the delay for both absorption and metabolism from inactive (prednisone) to active form (prednisolone). This model predicted free concentrations, which were then used to calculate total concentrations based on established binding constants.Results: Free prednisolone clearance (CLu/F) and volume of distribution (Vu/F) were scaled allometrically to body weight. The typical population estimates (95% confidence interval) were 54 (48–62) L/h/70 kg and 235 (203–274) L/70 kg, respectively. Additionally, the bioavailability parameter was found to decrease non‐linearly with the dose. Prednisolone cumulative exposure was not different between patients who responded at 3 months and those who did not.Conclusions: Robust pharmacokinetic targets are not yet clearly defined regarding toxicity or efficacy and are warranted in order to make a valuable contribution to prednisolone therapeutic drug monitoring in the context of SLE.
- 23 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (10) , 2854-2864
Open AccessPopulation pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity
Aims: Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE) to forecast free prednisolone concentrations and its association with disease activity.Methods: A total of 66 active SLE patients (adults and children) were included, and followed up prospectively (242 observations available). Plasma prednisolone concentrations were assessed using liquid chromatography‐mass spectrometry, and the data were analysed using Monolix software. The pharmacokinetic model was a one‐compartment open model with absorption lag time representing the delay for both absorption and metabolism from inactive (prednisone) to active form (prednisolone). This model predicted free concentrations, which were then used to calculate total concentrations based on established binding constants.Results: Free prednisolone clearance (CLu/F) and volume of distribution (Vu/F) were scaled allometrically to body weight. The typical population estimates (95% confidence interval) were 54 (48–62) L/h/70 kg and 235 (203–274) L/70 kg, respectively. Additionally, the bioavailability parameter was found to decrease non‐linearly with the dose. Prednisolone cumulative exposure was not different between patients who responded at 3 months and those who did not.Conclusions: Robust pharmacokinetic targets are not yet clearly defined regarding toxicity or efficacy and are warranted in order to make a valuable contribution to prednisolone therapeutic drug monitoring in the context of SLE.
- Open Access
- 21 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf031
Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance
- 21 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf031
Open AccessReply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance